Published in Ann Rheum Dis on November 01, 2006
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol (2008) 7.18
B cells as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 2.25
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2010) 1.55
Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum (2010) 1.37
Regulation of aicda expression and AID activity: relevance to somatic hypermutation and class switch DNA recombination. Crit Rev Immunol (2007) 1.19
BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol (2009) 1.18
Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies. Clin Exp Immunol (2012) 0.89
Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? Discov Med (2010) 0.87
Belimumab: First targeted biological treatment for systemic lupus erythematosus. J Pharmacol Pharmacother (2011) 0.80
Homeostatic T cell proliferation after islet transplantation. Clin Dev Immunol (2013) 0.79
Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura. Clin Exp Immunol (2015) 0.76
B cell phenotypes in patients with rheumatoid arthritis relapsing after Rituximab: Expression of B cell activating factor-binding receptors on B cell subsets. Clin Exp Immunol (2017) 0.75
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 5.99
An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science (2001) 5.73
B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med (1999) 4.52
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity (2004) 4.42
BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med (2004) 4.41
Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature (1994) 4.36
Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature (1991) 4.04
Induction of self-tolerance in mature peripheral B lymphocytes. Nature (1989) 4.02
Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity (2004) 4.00
Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol (2001) 3.92
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity (2001) 3.43
BAFF: a fundamental survival factor for B cells. Nat Rev Immunol (2002) 2.94
Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. J Immunol (1993) 2.86
BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity (2002) 2.75
Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol (2001) 2.75
Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol (2002) 2.16
The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol (2005) 2.16
Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med (1994) 2.15
The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J Exp Med (1996) 1.96
Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity. Eur J Immunol (1998) 1.80
Peripheral B cell maturation. I. Immature peripheral B cells in adults are heat-stable antigenhi and exhibit unique signaling characteristics. J Immunol (1992) 1.77
Space, selection, and surveillance: setting boundaries with BLyS. J Immunol (2006) 1.55
Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol (2001) 1.49
Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem (2004) 1.38
The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun (2005) 1.37
Peripheral B-cell maturation: the intersection of selection and homeostasis. Immunol Rev (2004) 1.26
Signaling thresholds and interclonal competition in preimmune B-cell selection. Immunol Rev (1997) 1.20
The role of BAFF in immune function and implications for autoimmunity. Immunol Rev (2005) 1.17
BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site. Biochemistry (2003) 1.08
The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation. Immunol Rev (2004) 1.07
Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann Rheum Dis (2003) 1.00
Homeostatic niche specification among naïve and activated B cells: a growing role for the BLyS family of receptors and ligands. Semin Immunol (2005) 0.99
Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors. Curr Dir Autoimmun (2005) 0.93
BLyS and B cell autoimmunity. Curr Dir Autoimmun (2003) 0.85
B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma (2002) 0.81
A therapeutic role for BLyS antagonists. Lupus (2004) 0.80